These new findings indicate that the current prostate cancer standard of care will upregulate IL1β in patients presenting with secondary lesions with an exclusive or predominant ARPOS status similarly to patients with metastatic tumors harboring mostly or entirely ARNEG tumor cells. This evidence concerns the gene IL1B and neoplasm.